Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | TYK2 | P29597 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3455442 | 0.86 | L3MBTL1 (0.44) | PPARDKDM4EPOLBRAB9AJAK2 | |
| SCHEMBL19868461 | 0.83 | KDM4E (0.41) | PPARDKDM4EPOLBRAB9ANFE2L2 | |
| SCHEMBL2646780 | 0.82 | PPARD (0.42) | PPARDKDM4EPOLBRAB9ANFE2L2 | |
| SCHEMBL1657082 | 0.79 | KDM4E (0.41) | PPARDKDM4EPOLBRAB9ANFE2L2 | |
| SCHEMBL4079671 | 0.74 | KDM4E (0.37) | PPARDKDM4EPOLBRAB9ANFE2L2 | |
| SCHEMBL7413114 | 0.73 | ALDH1A1 (0.50) | KDM4EL3MBTL1 | |
| SCHEMBL10970323 | 0.73 | NFE2L2 (0.59) | KDM4EPOLBRAB9ANFE2L2KEAP1 | |
| SCHEMBL1465207 | 0.72 | NFE2L2 (0.42) | KDM4EPOLBNFE2L2NAMPTSMN1; SMN2 | |
| SCHEMBL11185099 | 0.72 | ALDH1A1 (0.54) | KDM4EPOLBRAB9AL3MBTL1 | |
| SCHEMBL31434911 | 0.72 | MAPK1 (0.49) | PPARDKDM4EPOLBRAB9AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2239253-B1 | NOVEL PHENYLPYRROLE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2013-06-19 | — | — | EP | disclosed |
| US-8415359-B2 | Phenylpyrrole derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-04-09 | — | — | US | disclosed |
| US-20120022075-A1 | NOVEL PHENYLPYRROLE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-01-26 | — | — | US | disclosed |
| US-8017610-B2 | Phenylpyrrole derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-09-13 | — | — | US | disclosed |
| WO-2011095997-A1 | BENZAMIDE COMPOUNDS AS GLUCOKINASE ACTIVATORS AND THEIR PHARMACEUTICAL APPLICATION | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2011-08-11 | — | — | WO | disclosed |
| WO-2011095997-A1 | BENZAMIDE COMPOUNDS AS GLUCOKINASE ACTIVATORS AND THEIR PHARMACEUTICAL APPLICATION | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2011-08-11 | — | — | WO | disclosed |
| US-20110003787-A1 | NOVEL PHENYLPYRROLE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-01-06 | — | — | US | disclosed |
| EP-2239253-A1 | NOVEL PHENYLPYRROLE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2010-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003787-A1 | NOVEL PHENYLPYRROLE DERIVATIVE | GCKR, GCK, SLC5A1 | PPARD 1758/4885KDM4E 2858/4885POLB 4619/4885 |
| US-20120022075-A1 | NOVEL PHENYLPYRROLE DERIVATIVE | GCKR, GCK, SLC5A1 | PPARD 1758/4885KDM4E 2858/4885POLB 4619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.